ALLMedicine™ Bullous Pemphigoid Center

Jun 30th, 2022 - Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesion...

Jun 26th, 2022 - As autoimmune skin diseases, both bullous pemphigoid (BP) and dermatomyositis (DM) show significant associations with the major histocompatibility complex (MHC) region. In fact, the coexistence of BP and DM has been previously reported. Therefore,...

Jun 24th, 2022 - A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5 and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid. There is evidence that both terminal complement activation (via C5...

Jun 20th, 2022 - Practice Essentials Dyshidrotic eczema, also termed pompholyx, is a type of eczema (dermatitis). This skin condition is characterized by intensely itchy blisters that develop on the edges of the fingers, toes, palms, and soles of the feet. Dyshidr...

Jun 20th, 2022 - Practice Essentials Dyshidrotic eczema, also termed pompholyx, is a type of eczema (dermatitis). This skin condition is characterized by intensely itchy blisters that develop on the edges of the fingers, toes, palms, and soles of the feet. Dyshidr...

Jun 24th, 2022 - A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5 and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid. There is evidence that both terminal complement activation (via C5...

Jun 9th, 2022 - Bullous pemphigoid (BP) is a rare disease mainly affecting the elderly. BP is associated with significant morbidity and increased mortality secondary to increased risk of secondary infections, comorbid conditions, and serious side effects from hig...

Jun 8th, 2022 - ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity, participant-reported outcome me...

Jun 7th, 2022 - The study team plans to recruit 45 subjects from the autoimmune blistering disease clinic at Emory Dermatology Clinic. The plan is to improve the quality of future clinical trials in bullous pemphigoid (BP), the team will monitor repeated measurem...

May 26th, 2022 - The primary objective of the study is to demonstrate that dupilumab is superior to placebo in achieving sustained remission off oral corticosteroids (OCS) in patients with bullous pemphigoid (BP). The secondary objectives of the study are: To eval...

May 27th, 2022 - Eosinophilic GI diseases (EGIDs) often overlap with other eosinophil-associated diseases (EADs), which leads to greater health care costs, according to an analysis of the U.S. Optum Clinformatics claims database. EADs have gained increased attenti...

May 26th, 2022 - Eosinophilic GI diseases (EGIDs) often overlap with other eosinophil-associated diseases (EADs), which leads to greater health care costs, according to an analysis of the U. S.

Apr 21st, 2022 - Bullous pemphigoid, an immune-mediated condition chacterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs) that may result in treatment interruption or ce...

Apr 19th, 2022 - The Diagnosis: Epidermolysis Bullosa Our patient was found to have epidermolysis bullosa (EB), a rare genetic disease in which the superficial layers of the skin separate to form vesicles or bullae due to a mutation in the keratin 14 gene, KRT14.

Feb 10th, 2022 - Autoimmune bullous dermatoses (ABDs) develop due to antibodies directed against antigens within the epidermis or at the dermoepidermal junction. They are categorized histologically by the location of acantholysis (separation of keratinocytes), cli.